We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda Strengthens Its CAR-T Platform With GammaDelta Therapeutics Acquisition
Takeda Strengthens Its CAR-T Platform With GammaDelta Therapeutics Acquisition
Takeda Pharmaceuticals is expanding its off-the-shelf CAR-T cell program yet again, with the acquisition of GammaDelta Therapeutics, a company researching the unique abilities of gamma delta T-lymphocytes to attack blood cancers and solid tumors.